Two deaths have been filed with the U.S. Food and Drug Administration as adverse-event reports involving products sold as retatrutide, according to a CBS News report. The cases mark what appear to be among the first confirmed FDA-filed death reports connected to the gray-market retatrutide trade.
Retatrutide is an experimental drug under development by Eli Lilly. No version of retatrutide has been approved by any regulatory authority anywhere in the world. Despite that, products claiming to contain the compound are widely sold through online peptide vendors and other unverified sources.
The FDA has noted that details in the adverse-event reports are unverified, and it remains unclear whether retatrutide caused either death. Adverse-event reports document suspected associations, not proven causation.
What happened
According to CBS News, the first adverse-event report involves a 41-year-old woman with obesity who suffered cardiac arrest in July 2026 after obtaining retatrutide from what was described as an unreliable source. The product was listed as a suspect product in the filing.
The second report involves a 49-year-old patient who died in September 2026. CBS News reported that a licensed nurse convinced the patient to purchase retatrutide from an online peptide vendor. The patient experienced severe dehydration, malnutrition, and cardiac arrest prior to death.
In both cases, the products involved were obtained outside of any approved clinical trial or legitimate pharmaceutical supply chain. The FDA has not verified the contents of the products or confirmed a causal link between retatrutide and the deaths.
Why it matters
These reports add documented weight to enforcement arguments that unapproved retatrutide products pose acute patient-safety risks. While adverse-event reports do not establish causation, they are used by regulators to identify potential safety signals and inform enforcement priorities.
The cases also highlight the role of intermediaries — including a licensed nurse in the second case — in steering patients toward unverified online peptide vendors. That detail may draw attention from state licensing boards and federal regulators examining how unapproved peptides reach consumers.
For Eli Lilly, the reports underscore the reputational and safety concerns that can arise when an investigational drug is sold outside of clinical trials before receiving regulatory approval.
What to watch next
- Whether the FDA issues public warnings or enforcement actions specifically targeting retatrutide sold through online vendors.
- Whether state licensing boards investigate the nurse identified in the second adverse-event report.
- Whether Eli Lilly takes any public action regarding unauthorized products claiming to contain its compounds.
- Whether additional adverse-event reports linked to bootleg retatrutide emerge as awareness of the cases grows.
Sources
CBS News — Deaths reported to FDA linked to bootleg weight-loss drug
Industry information only. Not medical or legal advice.
